Your AI-Trained Oncology Knowledge Connection!
DUBLIN, Ohio--Neoprobe Corporation has announced that a patent granted to Jeffrey Schlom, PhD, of the National Cancer Institute, and David Colcher, PhD, of the University of Nebraska Medical Center, covers claims to composition of matter for a large group of second-generation monoclonal antibodies that target the tumor-associated antigen TAG-72.
ASCO--After more than a year of operating a teleoncology service, University of Kansas researchers have seen no discrepancies between consultations conducted via interactive video and subsequent on-site assessments. The University turned to teleoncology to better serve patients in sparsely settled areas of the state, Gary C. Doolittle, MD, co-director of the telemedicine service, said in his ASCO presentation in Philadelphia.
NEW BRUNSWICK, NJ--Confide, the first home collection HIV testing and counseling service, has received FDA approval and is now being test marketed in Texas and Florida. The test was developed by Direct Access Diagnostics, a Johnson & Johnson subsidiary based in Bridgewater, NJ, in conjunction with Chiron Corporation.
With the goal of protecting the economic security of people with AIDS (PWAs) who decide to sell their life insurance policies to obtain cash, a group of leading advocates for PWAs met in Los Angeles on March 22 to draft a set of standards
Prior to 1981, Kaposi sarcoma (KS) was considered a rare human cancer occurring primarily among elderly Italian and Jewish men of eastern European ancestry. I wrote a review of KS research and clinical experiences that appeared in CA: A
Treatment options for patients with acquired immune deficiency syndrome (AIDS)-related Kaposi's sarcoma (KS) have changed very little over the past decade. Research has been hampered by the absence of an accepted
PALM SPRINGS, Calif--The United Kingdom, not unlike the United States, is undergoing a period of radical change in the organization of cancer services, the status of the medical professionals delivering those services, and the climate for conducting clinical research, Ann Cull, PhD, said at the American Society for Psychiatric Oncology/AIDS meeting.
WASHINGTON--Joint ventures between community hospitals and university departments of oncology can offer significant benefits to both, but not unless all parties involved understand one another and formulate a well thought out program.
A study currently underway at the Medical College of Wisconsin is looking at why farmers do or do not follow safe-use guidelines when applying pesticides and is measuring their levels of pesticide exposure
WASHINGTON--Despite increasing complaints from physicians and patients, don't look for Congress to take any action in 1996 to remedy the problems that have evolved with the growth of managed care, a key Senate aide said at the national meeting of the Association of Community Cancer Centers (ACCC).
MONTREAL--A new instrument for measuring pain intensity--the visual analogue thermometer (VAT)--developed to overcome some of the disadvantages of the conventional visual analogue scale (VAS)--has proved "valid, accurate, and clinically useful" in two studies, say Manon Choinière, PhD, of the Burn Centre, Hotel-Dieu Hospital of Montreal and the University of Montreal, and Rhonda Amsel, MSc, of the Department of Psychology, McGill University.
Physicians today are facing more ethical dilemmas as patient decisions are being based less on beneficence and more on business models of success, says Sister Patricia Talone, ethics consultant, Mercy Health Corporation of Southeastern
BETHESDA, Md--Newly available from the NIH/NCI (NIH Publication 96-4104, April 1996) is a SEER monograph entitled Racial/Ethnic Patterns of Cancer in the United States, 1988-1992.
In the United States, the implementation of antibody testing in 1985 of all donated blood for human immunodeficiency virus type 1 (HIV-1) resulted in a substantial decrease in the transmission of HIV through blood transfusions. To further decrease
PHILADELPHIA--Forging ahead with change was the theme of the second annual meeting of the Association of Cancer Executives (ACE). And for most of the speakers, change meant adapting to the new reality of managed care and hospital mergers.
PHILADELPHIA--During his tenure at Brigham and Women's Hospital, Lawrence Shulman, MD, has been involved in two hospital mergers. The first, with Massachusetts General Hospital, was done in secrecy, while the latest, with the Dana-Farber Cancer Institute, has been an open process.
This timely and informative review describes the components of a cost-effectiveness analysis and provides useful commentary on various ways to measure them. It may be helpful, however, to take a step back and compare cost-effectiveness analysis to the other basic approaches to economic analysis.
WASHINGTON--In an experiment that may blur the line between therapeutic and preventive medications, researchers from the University of Wisconsin, Madison, plan to move a novel new compound to phase II testing in advanced cancer patients.
WASHINGTON--Employers, who first embraced managed care as a way to lower health care costs, are now joining together in buying coalitions to extract even greater price reductions from organizations such as HMOs from whom they purchase health care insurance for their employees.
It used to take Mike Natishak, Sr., his wife Mary Alice, and their 9-year-old son Mike Jr., 6 hours to make the weekly drive from their home in Apalachin, NY, to Boston Children's Hospital. They had to stay over at a hotel to be at the hospital the next morning. So in addition to travel expenses, the Natishaks each lost 2 days of work.
ASCO--Both forms of recombinant human platelet growth factor currently under study have been shown to enhance platelet recovery after myelosup-pressive chemotherapy without serious side effects. The first four clinical trials of the two products--pegylated megakaryocyte growth and development factor (MGDF, Amgen), which is linked to polyethylene glycol to improve its stability and half-life; and thrombopoietin (rhTPO, Genentech)--were presented at an ASCO scientific symposium.
NeXstar Pharmaceuticals made four DaunoXome-related presentations at the 9th NCI-EORTC Symposium on New Drugs in Cancer Therapy in Amsterdam, The Netherlands. Parkash S. Gill, MD, associate professor medicine and pathology at the
Rockville, Md --GenVec has begun a phase I study of its in vivo gene-based product, AdgvCD. 10, in 18 patients with liver metastases of colectoral cancer . An advenovirus vector modified to carry the cytosine deaminase gene will be administered directly into the hepatic tumor. The gene expresses an enzyme that converts 5-fluorocytosine,an oral anti-fungal agent , into the potent anticancer agent 5-fluorouracil.. The conversion occurs only at the site of gene expression, the company said.
PHILADELPHIA--The strategy of the Washington Hospital Center (WHC) cancer program for surviving managed care has been to enthusiastically embrace change, said Kenneth Samet, president of WHC, at the annual meeting of the Association of Cancer Executives (ACE).
BETHESDA, Md--At the 98th Meeting of the National Cancer Advisory Board (NCAB), Dr. Richard Klausner, director of the National Cancer Institute (NCI), congratulated everyone at the NCI on weathering the first year of structural changes under his new leadership.
PHILADELPHIA--When practice guidelines or pathways take financial considerations into account, they may be termed clinical financial pathways (CFPs). This technique was developed by Kent Giles, MPPM, vice president of development at PhyMatrix, a physician management company headquartered in West Palm Beach, Fla, and is currently being utilized by PhyMatrix to reduce unnecessary medical costs.
NEW YORK--All physicians, regardless of their specialty, must be prepared to treat HIV-infected patients, according to an expert from the Centers for Disease Control and Prevention. Although fears of nosocomial transmission of the virus are not unwarranted, much can be done to avoid it.
his excellent review analyzes ophthalmologic complications following high-dose irradiation of the orbit and surrounding structures as a necessary adjunct to the treatment of patients with carcinomas of the head and neck region. It confirms the critical importance of dose-fraction size in the production of radiation complications, especially in nerve tissue.
The failure to contain health-care costs and curtail growth is a growing national economic concern and public policy issue. The marketplace is rapidly changing how health care is paid for by moving from fee-for-service mechanisms to prospective payment, diagnosis-related groups, and increasing exclusion of some treatment(s).
Parsons and colleagues present an excellent summary of their clinical experience with ocular complications of radiotherapy for primary periocular malignancies, together with a retrospective review of the literature on this subject. The authors emphasize the roles of both total dose and dose-per-fraction in radiation-associated eye complications.
